Armata Pharmaceuticals (ARMP) News Today $2.06 +0.02 (+0.98%) As of 01/17/2025 04:10 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesOwnershipSEC FilingsShort Interest All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Rises By 203.3%Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) was the target of a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 18,500 shares, an increase of 203.3% from the December 15th total of 6,100 shares. Currently, 0.2% of the company's shares are short sold. Based on an average daily trading volume, of 10,700 shares, the short-interest ratio is currently 1.7 days.January 14, 2025 | marketbeat.comArmata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Up 125.9% in DecemberArmata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) was the recipient of a large increase in short interest during the month of December. As of December 15th, there was short interest totalling 6,100 shares, an increase of 125.9% from the November 30th total of 2,700 shares. Based on an average daily trading volume, of 9,000 shares, the short-interest ratio is presently 0.7 days. Approximately 0.1% of the company's stock are short sold.December 27, 2024 | marketbeat.comPromising Phase 2 Results for AP-PA02 Boost Armata Pharmaceuticals’ Investment AppealDecember 22, 2024 | markets.businessinsider.comArmata Pharma’s inhaled AP-PA02 shows positive results in Phase 2 studyDecember 20, 2024 | finance.yahoo.comArmata Pharmaceuticals (NYSEAMERICAN:ARMP) Earns "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $7.00 price target on shares of Armata Pharmaceuticals in a research report on Thursday.December 19, 2024 | marketbeat.comArmata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa InfectionDecember 19, 2024 | prnewswire.comSuparna Mishra SarkarDecember 16, 2024 | latimes.comArmata Pharmaceuticals Announces CMO Departure AgreementDecember 5, 2024 | markets.businessinsider.comArmata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual MeetingNovember 19, 2024 | prnewswire.comArmata Pharmaceuticals FY2024 EPS Raised by HC WainwrightArmata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Free Report) - Analysts at HC Wainwright boosted their FY2024 earnings per share (EPS) estimates for shares of Armata Pharmaceuticals in a research note issued to investors on Thursday, November 14th. HC Wainwright analyst J. Pantginis now forecasNovember 18, 2024 | marketbeat.comArmata Pharmaceuticals Extends Credit Agreement and CMO DepartsNovember 15, 2024 | markets.businessinsider.comArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate UpdateNovember 15, 2024 | finanznachrichten.deArmata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate UpdateNovember 13, 2024 | prnewswire.comArmata Pharmaceuticals (NYSEAMERICAN:ARMP) Receives Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $7.00 target price on shares of Armata Pharmaceuticals in a report on Tuesday.November 12, 2024 | marketbeat.comArmata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus BacteremiaNovember 12, 2024 | prnewswire.comArmata Pharmaceuticals Announces Structural Biology PublicationOctober 30, 2024 | prnewswire.comArmata Pharmaceuticals (AMEX:ARMP) Stock Quotes, Forecast and News SummaryOctober 18, 2024 | benzinga.comArmata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Sees Large Decline in Short InterestArmata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) saw a large decrease in short interest in September. As of September 30th, there was short interest totalling 3,400 shares, a decrease of 35.8% from the September 15th total of 5,300 shares. Based on an average daily volume of 8,100 shares, the short-interest ratio is presently 0.4 days. Currently, 0.0% of the company's stock are short sold.October 12, 2024 | marketbeat.comArmata Pharmaceuticals (NYSEAMERICAN:ARMP) Shares Down 2.2% - Time to Sell?Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Trading Down 2.2% - Here's What HappenedOctober 10, 2024 | marketbeat.comRakovina Therapeutics Inc. (RKV.V) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comArmata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Sees Large Increase in Short InterestArmata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) saw a significant increase in short interest in the month of August. As of August 31st, there was short interest totalling 7,000 shares, an increase of 11.1% from the August 15th total of 6,300 shares. Based on an average daily volume of 9,300 shares, the short-interest ratio is presently 0.8 days. Approximately 0.1% of the company's shares are sold short.September 18, 2024 | marketbeat.comARMP Armata Pharmaceuticals, Inc.September 9, 2024 | seekingalpha.comArmata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 5, 2024 | prnewswire.comTG1M.SG,0P00015OC5,0 (TG1M.SG)September 3, 2024 | ca.finance.yahoo.comArmata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Up 133.3% in AugustArmata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) saw a significant growth in short interest during the month of August. As of August 15th, there was short interest totalling 6,300 shares, a growth of 133.3% from the July 31st total of 2,700 shares. Based on an average daily volume of 10,400 shares, the short-interest ratio is presently 0.6 days. Currently, 0.1% of the company's stock are sold short.August 29, 2024 | marketbeat.comArmata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research SymposiumAugust 26, 2024 | prnewswire.comSilexion Therapeutics CorpAugust 24, 2024 | money.usnews.comShort Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Drops By 12.9%Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) saw a large decline in short interest in the month of July. As of July 31st, there was short interest totalling 2,700 shares, a decline of 12.9% from the July 15th total of 3,100 shares. Approximately 0.0% of the company's shares are sold short. Based on an average daily volume of 11,700 shares, the short-interest ratio is presently 0.2 days.August 18, 2024 | marketbeat.comArmata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial OfficerAugust 15, 2024 | prnewswire.comBuy Rating Justified by Armata Pharmaceuticals’ Advancements in Bacteriophage Therapeutics and Strategic PartnershipsAugust 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Armata Pharmaceuticals Amid Positive Earnings and Promising Clinical ProgressAugust 15, 2024 | markets.businessinsider.comArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate UpdateAugust 14, 2024 | finanznachrichten.deArmata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate UpdateAugust 13, 2024 | prnewswire.comArmata Pharmaceuticals (NYSEAMERICAN:ARMP) Trading Down 2.8%Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Shares Down 2.8%August 2, 2024 | marketbeat.comArmata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02July 30, 2024 | prnewswire.comInnoviva’s (INVA) Stock Is Thriving With Strategic Investments Pay-OffJuly 28, 2024 | msn.comArmata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa InfectionJuly 11, 2024 | prnewswire.comArmata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024July 10, 2024 | prnewswire.comArmata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Down 60.9% in JuneArmata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) was the recipient of a significant drop in short interest in June. As of June 15th, there was short interest totalling 900 shares, a drop of 60.9% from the May 31st total of 2,300 shares. Currently, 0.0% of the company's stock are sold short. Based on an average daily trading volume, of 14,700 shares, the short-interest ratio is presently 0.1 days.June 28, 2024 | marketbeat.comArmata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Sees Large Growth in Short InterestArmata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) saw a large growth in short interest in May. As of May 31st, there was short interest totalling 2,300 shares, a growth of 187.5% from the May 15th total of 800 shares. Currently, 0.0% of the company's stock are sold short. Based on an average trading volume of 15,000 shares, the short-interest ratio is presently 0.2 days.June 13, 2024 | marketbeat.comArmata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Sees Significant Increase in Short InterestArmata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) was the recipient of a significant increase in short interest in the month of April. As of April 30th, there was short interest totalling 10,700 shares, an increase of 8.1% from the April 15th total of 9,900 shares. Approximately 0.1% of the company's shares are sold short. Based on an average daily trading volume, of 16,100 shares, the short-interest ratio is currently 0.7 days.May 16, 2024 | marketbeat.comBuy Rating Affirmed for Armata Pharmaceuticals Amid Progress and Strategic Financial MovesMay 8, 2024 | markets.businessinsider.comArmata Pharmaceuticals' (ARMP) "Buy" Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and issued a $7.00 target price on shares of Armata Pharmaceuticals in a research note on Wednesday.May 8, 2024 | marketbeat.comArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate UpdateMay 8, 2024 | finanznachrichten.deARMP Stock Earnings: Armata Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024May 8, 2024 | investorplace.comArmata Pharmaceuticals Q1 2024 Earnings: Narrower Losses and Strategic AdvancesMay 7, 2024 | finance.yahoo.comArmata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate UpdateMay 7, 2024 | prnewswire.comArmata Pharmaceuticals (NYSEAMERICAN:ARMP) Trading Down 1.8%Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Shares Down 1.8%April 13, 2024 | marketbeat.comBuy Rating Affirmed for Armata Pharmaceuticals Amid Progress in Bacteriophage Therapy DevelopmentMarch 25, 2024 | markets.businessinsider.comArmata Pharmaceuticals Inc (ARMP) Earnings: Navigates Through R&D to Narrow LossesMarch 23, 2024 | finance.yahoo.com Get Armata Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARMP and its competitors with MarketBeat's FREE daily newsletter. Email Address ARMP Media Mentions By Week ARMP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARMP News Sentiment▼0.470.48▲Average Medical News Sentiment ARMP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARMP Articles This Week▼11▲ARMP Articles Average Week Get Armata Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARMP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Y-mAbs Therapeutics News Today Voyager Therapeutics News Today LifeVantage News Today True Drinks News Today iTeos Therapeutics News Today Aquestive Therapeutics News Today Immutep News Today Neurogene News Today Olema Pharmaceuticals News Today Atyr PHARMA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSEAMERICAN:ARMP) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Armata Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Armata Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARMP Stock Alerts